<--- Back to Details
First PageDocument Content
Growth factors / Hematology / Oncology / Filgrastim / Cytokines / Granulocyte colony-stimulating factor / Febrile neutropenia / Neutropenia / Acute myeloid leukemia / Medicine / Biology / Amgen
Growth factors
Hematology
Oncology
Filgrastim
Cytokines
Granulocyte colony-stimulating factor
Febrile neutropenia
Neutropenia
Acute myeloid leukemia
Medicine
Biology
Amgen

FOOD AND DRUG ADMINISTRATION

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 25,90 KB

Share Document on Facebook

Similar Documents

Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Biotechnology / Biology / Medicine / Recombinant proteins / Specialty drugs / Biosimilar / Drugs / Biopharmaceutical / Trastuzumab / Mylan / Pegfilgrastim / Filgrastim

Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

DocID: 1q6vz - View Document

Medical research / Medicine / Health / Clinical research / Bblingen / Microcars / Smart / Clinical trial / Biosimilar / Filgrastim

“You Don’t Know What You’re Missing” Evaluating Competitor Clinical Trials with the BizInt Smart Charts Product Family November 2013

DocID: 1mfkn - View Document

[ Industry Watch ] INDIA Intas Plans Filgrastim launch in North America, Europe

DocID: 1kixC - View Document

Orphan drugs / Organofluorides / Pyridines / Organochlorides / Piperazines / Sunitinib / Renal cell carcinoma / Chronic myelogenous leukemia / Sorafenib / Medicine / Chemistry / Oncology

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

DocID: 1fBTU - View Document